Oxford Haemophilia & Thrombosis Centre; NIHR Oxford Biomedical Research Centre
University of Aberdeen; Thrombosis & Haemostasis laboratory
My main research interest lies in fibrinolysis (degradation of a blood clot) and how the clot structure alters the rate of lysis. I am currently working with Dr Nicola Curry and her team of clinicians at the Oxford Haemophilia and Thrombosis Centre at the Churchill Hospital.
My work focuses on two different types of fibrinogen replacement administered to trauma patients. Fibrinogen is the key pro-coagulant factor required for stable clot formation. Patients recruited to the Fibrinogen Early in Severe Trauma StudY (FEISTY) were given one of two treatments: cryoprecipitate or fibrinogen concentrate. My research investigates the differences in clot structure and strength between the two fibrinogens, and how this correlates with clinical outcome.
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
Whyte CS. et al, (2020), J Thromb Haemost
Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyzer.
Morrow GB. et al, (2020), J Thromb Haemost
Functional plasminogen activator inhibitor 1 is retained on the activated platelet membrane following platelet activation
Morrow GB. et al, (2019), Haematologica, haematol.2019.230367 - haematol.2019.230367
Coagulation status of critically ill patients with liver disease assessed using a novel thrombin generation analyser
Morrow GB. et al, (2019), BRITISH JOURNAL OF HAEMATOLOGY, 185, 137 - 137
UTP is not a biased agonist at human P2Y11 receptors
Morrow GB. et al, (2014), Purinergic Signalling, 10, 581 - 585